Flixabi is a biosimilar medicine to the original biologic drug infliximab, which is widely used in the treatment of various autoimmune diseases. It is specifically designed to mimic the therapeutic effects of infliximab, targeting and neutralizing tumor necrosis factor-alpha (TNF-alpha), a substance in the body that can cause inflammation and lead to immune system diseases. Flixabi is administered via intravenous infusion and is commonly prescribed for conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By inhibiting the action of TNF-alpha, Flixabi helps to reduce inflammation, alleviate symptoms, and prevent disease progression, offering patients an effective treatment option for managing their conditions.